On the stock market since 1975, it operates in the world of health and science. It has 2 employees. Now — the numbers.
Executives buying with their own money is usually read as confidence in the company’s future.
An investor who bought at the very peak is down 100% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 12 months, company executives reported 10 buys and 0 sells. Management buying with its own money is usually read as a good sign.
It pays out $4.00 per share each year — regular cash for whoever holds the stock.
The stock sits at $0.0001. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
Since the drop from its peak, buyer appetite hasn’t come back.
On our five-subject report card, CHCR sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: CHCR is a high-risk stock — not yet profitable, and its future rides on its product catching on.